Istvan Petak, Founder and Chief Scientific Officer at Genomate Health, shared on LinkedIn:
“Hello, Institute of Advanced Studies Koszeg (iASK)!
Hello, IOSI Oncology Institute of Southern Switzerland – EOC), Teaching Conference at Ospedale San Giovanni, Bellinzona!
Hello, Best of ASCO (American Society of Clinical Oncology2025, Cluj, Transylvania, Romania!
Over the past two weeks, I’ve continued my journey across countries and conferences — each contributing in its own way to shaping a better future in cancer care.
It was a great pleasure and honor to join the discussion in the beautiful town of Kőszeg on how we can create a future where AI and other technological breakthroughs improve universal access to the best possible care for cancer patients. Thank you, iASK, for building bridges between medical and social sciences — we need dialogue and trust more than ever to ensure that innovation genuinely improves lives.
My gratitude also to Ambassador Gergo Kocsis for his inspiring reflections on the United Nations’s 80-year journey and future; to Ludvik Toplak, Rector, and Luka Martin Tomažič, Vice-Rector for Science at Alma Mater Europaea, for sharing their vision for collaboration; and to Miszlivetz Ferenc, the founder and director of iASK for bringing us all together.
Thank you, IOSI, for inviting me to Bellinzona, Switzerland, to present at your Teaching Conference and discuss advances in computational reasoning and AI, and how they can transform cancer treatment and clinical trial design — by matching therapies to the entire molecular profile rather than just focusing on single genetic changes. I deeply appreciate the invitation from Anastasios Stathis, Prof MD, and the warm hospitality and engaging discussions provided by Silke Gillessen, Medical and Scientific Director of IOSI.
It’s always a privilege to return to Best of ASCO, organized by adrian udrea and his world-class team at Medisprof . Thank you, Adrian, for inviting me once again to speak about ‘Developmental Therapeutics – IO and Molecular and Tumor Biology.’
We discussed abstracts selected by ASCO: liquid biopsy is becoming an increasingly reliable source of information, and immune checkpoint inhibitors in solid tumor transplant patients, novel therapies that sound like science fiction: double-target monoclonal antibodies in small cell lung cancer, mRNA-encoded bispecific T-cell engager antibodies, produced in vivo in the liver, linking cancer cells directly to T-cells.
It was also inspiring to learn from an outstanding international faculty: Dr. Magdolna Dank, E. Gabriela Chiorean, MD, FASCO, PhD, Dr Rob Rutledge, Arantzazu Barquín García, Delvys Rodriguez-Abreu, MD, PhD, Alberto Jacobo Cunquero Tomás, and Santiago Cabezas-Camarero M.D. PhD.
Finally, I want to highlight Gabriela Ilie, PhD Ilie’s remarkable work on the importance of social and mental support in improving patient outcomes — and in preventing burnout among the dedicated doctors who fight for cancer patients every day.”
More posts featuring Istvan Petak on OncoDaily.